Turning Point Brands (TPB) Q1 2026 earnings review
Modern Oral Land Grab Crushes Near-Term Profitability
Turning Point Brands is aggressively sacrificing short-term earnings to capture market share in the booming Modern Oral (nicotine pouch) category. While Q1 consolidated revenue grew an impressive 16.8% YoY to $124.3 million—driven entirely by a 48.1% surge in the Stoker's segment—the bottom line took a severe hit. Net Income fell 19% and Adjusted EBITDA dropped 6.5% as SG&A expenses exploded by 53% to fund sales, marketing, and a new UFC partnership. The legacy Zig-Zag business is being starved of resources and collapsed 22.4%. Management is leaning heavily into this transition: FY26 guidance projects a massive $210-$225 million in Modern Oral net sales, but anticipates Adjusted EBITDA to plummet to $70-$90 million (a ~33% decline from FY25's ~$119.5 million). Investors must accept significant margin pain today for the promise of scale tomorrow.
🐂 Bull Case
Stoker's segment sales rocketed 48.1% YoY to $87.6 million. The raised full-year Modern Oral net sales guidance ($210-$225M) proves the aggressive go-to-market investments are yielding tremendous volume growth and market share gains.
The company holds $192.4 million in cash, providing a substantial liquidity buffer to absorb the planned EBITDA compression without stressing the balance sheet.
🐻 Bear Case
FY26 Adjusted EBITDA guidance of $70-$90 million implies a catastrophic margin degradation compared to FY25's ~$119.5 million. The cost of acquiring Modern Oral customers is currently destroying bottom-line growth.
Zig-Zag segment sales plummeted 22.4% to $36.7 million. The 'opportunity cost' of reallocating resources away from this legacy cash cow is accelerating.
⚖️ Verdict: ⚪
Neutral. The volume growth in Modern Oral is undeniably spectacular, but the structural step-down in EBITDA to fund it is severe. Until the company proves these new cohorts have high retention rates and can transition to profitable unit economics, the stock is a high-risk transition play.
Key Themes
SG&A Explosion Compresses Margins
The cost of competing in the Modern Oral category is staggering. Consolidated SG&A spiked 53.2% YoY to $55.8 million. Management attributes this to modern oral-related sales and marketing investments (including the new TKO/UFC partnership) and increased outbound freight costs. As a result, operating income was nearly sliced in half, dropping from $23.2 million to $12.5 million.
Zig-Zag Segment Capitulation
The decline in Zig-Zag is accelerating. Sales fell 22.4% YoY to $36.7 million, following declines of 13% in 25Q4 and 11% in 25Q3. While management previously framed this as an anticipated 'opportunity cost' of pivoting to pouches, the magnitude of the drop removes a massive pillar of legacy cash flow that was supposed to fund the Modern Oral transition.
Aggressive Guidance Hike for Modern Oral
Management significantly raised its FY26 guidance for Modern Oral Net Sales to $210-$225 million (up from the $180-$190 million forecast given in the prior quarter). To put this in perspective, total Modern Oral net sales in FY25 were likely around $130M. This implies phenomenal underlying volume growth and confirms that their aggressive distribution and merchandising strategies are working.
Tariff Costs Are Biting
Tariffs on imported pouches are actively hitting the P&L. The Q1 adjusted EBITDA reconciliation includes a $5.9 million add-back for 'Tariff adjustment' (tariffs subject to refund). This dragged Stoker's segment gross margin down to 54.0% from 57.5% a year ago. The urgency to qualify U.S. manufacturing lines (previously targeted for H1 2026) is extremely high to mitigate this margin drain.
Other KPIs
Reversing. Down 6.5% YoY. Despite adding back $5.9M in tariff adjustments and $2.9M in stock-based compensation, the metric still contracted due to the massive SG&A marketing load.
Stable. Comprised of $192.4 million in cash and $72.6 million of revolving credit capacity. The company burned $30 million in cash during the quarter (Operating Cash Flow was -$22.3M, largely driven by a $21.7M inventory build), but the balance sheet remains strong enough to weather the investment phase.
Guidance
Accelerating. This is a massive upgrade from the $180-$190 million initial guidance provided in Q4 2025. It demonstrates extreme confidence in the TKO/UFC partnership and expanded retail distribution.
Reversing sharply. This is the most crucial number in the report. In FY25, the company generated ~$119.5 million in Adjusted EBITDA. The midpoint of $80 million implies a ~33% YoY structural collapse in profitability as the company pays up for customer acquisition and slotting fees.
Key Questions
Path to Modern Oral Profitability
With FY26 EBITDA guided down to $70-$90 million, at what specific Modern Oral revenue run-rate do you expect this segment to cross the threshold into Adjusted EBITDA accretion rather than dilution?
Zig-Zag Floor
Zig-Zag sales decelerated to a 22.4% decline this quarter. Have we reached the bottom of the 'opportunity cost' from reallocating resources, or should we model further double-digit declines for the remainder of the year?
Tariff Recovery and Domestic Production
You added back $5.9 million in tariff adjustments this quarter. What is your degree of confidence in the actual refund of these tariffs, and is your timeline to qualify domestic U.S. manufacturing lines still on track for H1 2026 to eliminate this headwind?